Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health (ELAN) filed its Q3 2025 10‑Q, reporting revenue of $1,137 million, up from $1,030 million a year ago. Gross profit was $607 million. The quarter showed a net loss of $34 million (basic and diluted EPS of $(0.07)), compared to a prior-year period boosted by a $640 million gain on an asset sale. Year-to-date net income was $44 million.
Pet Health revenue was $533 million and Farm Animal totaled $593 million. Operating cash flow for the first nine months reached $452 million. Cash was $505 million, and long‑term debt (excluding finance lease) was $3,769 million, down from $4,321 million at year‑end. In May, Elanco monetized certain future XDEMVY royalties for $295 million, recorded as a $300 million liability with a 16.2% effective interest rate. Subsequent to quarter‑end, the company refinanced debt with new facilities and fully repaid its prior Term Loan B; the weighted‑average effective interest rate decreased to 5.77% as of October 31, 2025. Shares outstanding were 496,863,473 as of October 31, 2025.
Elanco Animal Health (ELAN) furnished a Current Report announcing results for the fiscal quarter ended September 30, 2025, along with guidance for the full year and fourth quarter of 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025.
The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.
Elanco Animal Health (ELAN) reported that President, CEO and Director Jeffrey N. Simmons acquired 125.0221 deferred stock units on 10/31/2025 at $22.15 per unit. Following this transaction, he beneficially owns 18,224.6156 derivative securities, held as direct ownership.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) officer Rajeev A. Modi reported a routine insider transaction on a Form 4. On 10/31/2025, he acquired 63.8655 Deferred Stock Units (DSUs) in a transaction coded “A.” Following this activity, he beneficially owned 7,163.1698 derivative securities, held directly. The filing lists a $22.15 price for the derivative security. Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent, and DSUs settle in cash or shares following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) amended its senior secured first-lien credit facility on October 31, 2025, executing Amendment No. 3 to refinance a portion of existing term debt and adjust covenants. The company added three tranches: $1,100,000,000 in new U.S. dollar term loans maturing on October 31, 2032, a €400,000,000 euro-denominated term loan tranche maturing on April 30, 2029, and $540,000,000 in farm credit term loans maturing on October 31, 2032.
Elanco used proceeds from these facilities, together with cash on hand, to refinance all outstanding borrowings under its term loan B due 2027 and to pay related fees and expenses. JPMorgan Chase Bank acts as administrative agent and U.S./Canadian collateral agent, with Wilmington Trust as non-U.S./non-Canadian collateral agent and security trustee.
Elanco Animal Health (ELAN): CEO Form 4 filing. President, CEO and Director Jeffrey N. Simmons reported an acquisition of 129.2829 deferred stock units on 10/17/2025 (Transaction Code A). The filing shows a $21.42 price of the derivative security and a post‑transaction balance of 18,099.5935 deferred stock units held directly.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year in accordance with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) reported an insider transaction by Executive Vice President Rajeev A. Modi. On 10/17/2025, he acquired 66.042 deferred stock units (DSUs) at $21.42, bringing his directly held DSUs to 7,099.3043.
Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, DSUs settle in cash or shares following termination of employment or during a specified future year.
Elanco Animal Health (ELAN): Schedule 13G filing shows BlackRock, Inc. reported beneficial ownership of 44,021,766 shares of common stock, representing 8.9% of the class as of 09/30/2025. BlackRock reports sole voting power over 42,268,742 shares and sole dispositive power over 44,021,766 shares, with no shared voting or dispositive power.
BlackRock filed as a parent holding company (HC) and certified the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco. The filing notes that various persons have rights to dividends or sale proceeds through managed accounts, and no single person’s interest exceeds five percent of total outstanding common shares.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction dated
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported on
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
